SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

SK bioscience and Sanofi have announced positive results from the Phase II study of their 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202). The vaccine demonstrated positive safety and immunogenicity data in infants. The companies plan to start Phase III trials in the first half of 2024. The Phase II clinical trial evaluated the safety and immunogenicity of GBP41..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms

First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion

Telix Pharmaceuticals has announced the dosing of the first patient in a Phase II study of TLX250-CDx, an imaging agent that targets carbonic anhydrase (CAIX) and is being investigated across a range of cancer indications. The STARBURST study will explore CAIX expression in patients with diverse solid tumours for potential diagnostic and therapeutic applications. Tumours expressing CAIX are typi..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 20.
  • textsms